{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T09:13:26Z","timestamp":1773134006891,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-CD20 therapies are widely used in patients with multiple sclerosis (pwMS). Recognition of rare adverse reactions to these therapies is therefore important.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To report dermatological and gastrointestinal adverse reactions in a single-center cohort of ocrelizumab treated pwMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analysis conducted at a multiple sclerosis outpatient clinic of Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany, between March 2020 and February 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 447 ocrelizumab treated pwMS, 8 (1.8%) developed dermatological adverse reactions after a median (range) of 20.5 (6-72) months following start of therapy, including lichen planus (n=2), rosacea (n=1), psoriatic arthritis (n=1), guttate psoriasis (n=1), psoriasis vulgaris (n=1), nail psoriasis (n=1) and palmoplantar psoriasis (n=1). Another 5 (1.1%) patients developed gastrointestinal adverse reactions 24 (0.25-77) months after starting therapy, including Crohn\u2019s disease (n=1), toxic colitis (n=1), lymphocytic colitis (n=1), perforated appendicitis (n=1) and acute cholecystitis (n=1). Due to these adverse reactions, ocrelizumab was stopped in 7\/13 patients. At last follow-up, adverse reactions had completely improved in 4\/13, incompletely improved in 6\/13, and persisted in 3\/13 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinicians should be aware of dermatological and gastrointestinal adverse reactions associated with ocrelizumab, which can develop from a few weeks up to six years after start of therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1753387","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:24:56Z","timestamp":1773084296000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dermatological and gastrointestinal adverse reactions in ocrelizumab treated patients with multiple sclerosis: a case series"],"prefix":"10.3389","volume":"17","author":[{"given":"Lena K.","family":"H\u00f6pner","sequence":"first","affiliation":[{"name":"Department of Neurology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella","family":"Marschall","sequence":"additional","affiliation":[{"name":"Department of Neurology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Schindler","sequence":"additional","affiliation":[{"name":"Department of Neurology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vilmar","family":"Frauendorf","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, MEOCLINIC GmbH","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"B\u00f6hmig","sequence":"additional","affiliation":[{"name":"Dr. Spitz & Kollegen, Practice For Gastroenterology","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Rakers","sequence":"additional","affiliation":[{"name":"Department of Neurology, Universit\u00e4tsklinikum Jena","place":["Jena, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Karimi","sequence":"additional","affiliation":[{"name":"Pathologie M\u00fcnchen-Nord, practice for pathology","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudius","family":"Faber","sequence":"additional","affiliation":[{"name":"Pathologie M\u00fcnchen-Nord, practice for pathology","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klemens","family":"Ruprecht","sequence":"additional","affiliation":[{"name":"Division of Neuroimmunology, Department of Neurology, University of Heidelberg","place":["Heidelberg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Otto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.10.1620","article-title":"Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis","volume":"62","author":"Stuve","year":"2005","journal-title":"Arch Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"CD013874","DOI":"10.1002\/14651858.CD013874.pub3","article-title":"Rituximab for people with multiple sclerosis","volume":"3","author":"Filippini","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241232277","article-title":"Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review","volume":"30","author":"Emma","year":"2024","journal-title":"Mult Scler"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/art.22811","article-title":"Development of psoriasis after B cell depletion with rituximab","volume":"56","author":"Dass","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1186016","article-title":"Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review","volume":"14","author":"Quesada-Simo","year":"2023","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241303479","article-title":"Ofatumumab-associated colitis: A case report","volume":"31","author":"Patel","year":"2025","journal-title":"Mult Scler"},{"key":"B12","unstructured":"Ocrevus prescribing information to include warnings for clotis and PML\n          \n          \n          \n          2022"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1111\/ddg.15777","article-title":"Oral lichen planus in a patient treated with anti-CD20 monoclonal antibodies","volume":"23","author":"Chan","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"B15","doi-asserted-by":"publisher","first-page":"104763","DOI":"10.1016\/j.msard.2023.104763","article-title":"Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review","volume":"75","author":"Tolaymat","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11995-6","article-title":"Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis","volume":"271","author":"Rodriguez de Vera Gomez","year":"2024","journal-title":"J Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903066726","article-title":"Type I IFNs and their role in the development of autoimmune diseases","volume":"8","author":"Burdick","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"B19","doi-asserted-by":"publisher","first-page":"103832","DOI":"10.1016\/j.msard.2022.103832","article-title":"Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis","volume":"63","author":"Porwal","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.02.030","article-title":"A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review","volume":"22","author":"Shahmohammadi","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2025-ANZAN.97","article-title":"Ocrelizumab induced colitis","volume":"7","author":"Potts","year":"2025","journal-title":"BMJ Neurol Open"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241260564","article-title":"Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis","volume":"30","author":"Kolsche","year":"2024","journal-title":"Mult Scler"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10679-3","article-title":"Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients","volume":"268","author":"Sankari","year":"2021","journal-title":"J Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"103021","DOI":"10.1016\/j.msard.2021.103021","article-title":"Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population","volume":"53","author":"Coban","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3154856","DOI":"10.1155\/2019\/3154856","article-title":"Oral lichenoid reaction: an uncommon side effect of rituximab","volume":"2019","author":"Giudice","year":"2019","journal-title":"Case Rep Dent"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_517_24","article-title":"Rituximab induced lichen planus","volume":"16","author":"Mannu","year":"2025","journal-title":"Indian Dermatol Online J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1038\/s41467-023-39761-2","article-title":"Whole genome sequencing identifies genetic variants associated with neurogenic inflammation in rosacea","volume":"14","author":"Deng","year":"2023","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11795735221109674","DOI":"10.1177\/11795735221109674","article-title":"Alopecia in multiple sclerosis patients treated with disease modifying therapies","volume":"14","author":"Porwal","year":"2022","journal-title":"J Cent Nerv Syst Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2050313X20919614","DOI":"10.1177\/2050313X20919614","article-title":"Ocrelizumab-induced alopecia areata-A series of five patients from Ontario, Canada: A case report","volume":"8","author":"Chin","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/his.15120","article-title":"Histologic manifestations of ocrelizumab-associated intestinal and hepatic injury in patients with multiple sclerosis","volume":"84","author":"Challa","year":"2024","journal-title":"Histopathology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52032","article-title":"Two cases of acute diverticulitis following ocrelizumab infusion in patients with multiple sclerosis","volume":"16","author":"Vigilante","year":"2024","journal-title":"Cureus"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2021.0582","article-title":"Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis","volume":"34","author":"Barnes","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"102279","DOI":"10.1016\/j.msard.2020.102279","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis","volume":"44","author":"Baker","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B34","doi-asserted-by":"publisher","first-page":"105900","DOI":"10.1016\/j.msard.2024.105900","article-title":"The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis","volume":"91","author":"Coerver","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12326","article-title":"Fumaric acid esters in psoriasis and multiple sclerosis","volume":"39","author":"Zecca","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn\u2019s disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"17562864211035542","DOI":"10.1177\/17562864211035542","article-title":"Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders","volume":"14","author":"Brummer","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"B39","doi-asserted-by":"publisher","first-page":"103312","DOI":"10.1016\/j.autrev.2023.103312","article-title":"Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders","volume":"22","author":"Konen","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.02.012","article-title":"Increased incidence and prevalence of psoriasis in multiple sclerosis","volume":"13","author":"Marrie","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.22037\/ghfbb.v18i2.3105","article-title":"Global prevalence and incidence of inflammatory bowel disease: a systematic review and meta-analysis of population-based studies","volume":"18","author":"Heydari","year":"2025","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514564490","article-title":"A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult Scler"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231195854","article-title":"Immune-mediated colitis associated with ocrelizumab: A new safety risk","volume":"29","author":"Kim","year":"2023","journal-title":"Mult Scler"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13662","article-title":"Induction of psoriatic scalp and nail lesions in a patient treated with Ofatumumab: A potential autoimmune dysregulation induced by anti-CD 20 therapy","volume":"30","author":"Herzum","year":"2024","journal-title":"Skin Res Technol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1753387\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:24:57Z","timestamp":1773084297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1753387\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2026.1753387"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1753387","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"article-number":"1753387"}}